Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Galsomes
- Development stage
- Preclinical
- Lead developer
- Ghent University
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular
01
Overview
Galsomes are an mRNA vaccine platform characterized by the encapsulation of uridine-modified mRNA within lipid nanoparticles, adjuvanted with alpha-galactosylceramide. This design aims to enhance immune responses by leveraging the adjuvant properties of alpha-galactosylceramide, which stimulates invariant natural killer T (iNKT) cells, in addition to the antigen-specific T cell response induced by mRNA vaccination. Preclinical studies have evaluated Galsomes for applications in cancer vaccines (e.g., Galsome-NEO) and therapeutic HIV vaccination, demonstrating robust antigen-specific CD8+ T cell responses and cytolytic activity in animal models[1][5]. The technology has also been explored as a prophylactic vaccine platform against various infectious diseases[6].
- Other names
- Galsome-NEOmRNA-galsomesGalsome-MOMP
02
Targets
CD1D (Tumor-associated macrophage/myeloid-derived suppressor cell CD1d complex)MHC I (MHC class I})iNKT TCR (Invariant natural killer T-cell receptor)
Beyond the preview
Go deeper on Galsomes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Galsomes.